PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 100
- 主要终点
- Myocardial Perfusion Reserve
研究概览
简要总结
Some people experience chest pain and shortness of breath, but when they have tests, no blockages are found in their main heart arteries. The most common cause of symptoms is related to abnormalities in the small blood vessels, also known as 'small vessel angina' or Coronary Microvascular Dysfunction (CMD). Currently, the diagnosis of CMD requires additional measurements of blood flow in the heart vessel during a minimally invasive procedure known as a coronary angiogram.
CMD affects many people and can lead to repeated hospital visits and a lower quality of life, and diagnosing the condition leads to better patient outcomes. However, there are still no widely available, proven treatments for this condition and therefore several patients remain symptomatic.
This study aims to find better ways to treat CMD, especially by understanding how the heart uses energy and how this might relate to symptoms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Angina with non-obstructive coronary arteries
排除标准
- •Significant epicardial coronary stenoses
- •Inability to carry out bike exercise
- •Contra-indication to adenosine administration
- •Insulin usage with frequent hypoglycaemic episodes
研究组 & 干预措施
Empagliflozin Therapy Arm
Empagliflozin 10mg OD
干预措施: Empagliflozin 10mg OD (Drug)
结局指标
主要结局
Myocardial Perfusion Reserve
时间窗: 8 weeks
Perfusion Cardiac Magnetic Resonance Imaging
次要结局
未报告次要终点